Comparative Pharmacology
Head-to-head clinical analysis: CLENZ LYTE versus CO LAV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLENZ LYTE versus CO LAV.
CLENZ-LYTE vs CO-LAV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colon lavage solution that osmotically induces diarrhea to cleanse the colon.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Oral: 4 L (or 240 mL every 10 minutes) administered the evening before colonoscopy; alternatively, 2 L (or 240 mL every 10 minutes) plus 2 L of clear liquids given in split doses (first 1-2 L evening before, remaining in morning of procedure).
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
None Documented
None Documented
Not applicable; systemic absorption is negligible (plasma levels below detection limits). Clinical effect is localized to gastrointestinal tract.
Unknown
Primarily fecal (approximately 95%) as unabsorbed polyethylene glycol; negligible renal excretion (<5%) as intact polymer.
CO-LAV is not a recognized drug. Please check the drug name.
Category C
Category C
Laxative
Laxative/Bowel Evacuant